Mumbai, May 17 (Reporter) Glenmark Pharma said on Friday it has received final approval from the United States Food and Drug Administration (USFDA) for its drug to be used in the treatment of glaucoma. Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. The symptoms can start so slowly that one may not notice them. The company said its drug Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%–0.5%, has been determined by the FDA to be bioequivalent and therapeutically equivalent to Combigan Ophthalmic Solution, 0.2%–0.5%, of North Chicago headquartered American pharmaceutical company AbbVie. The drug will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. According to the sales data compiled by American health information technology and clinical research company IQVIA, for the 12-month period ending March 2024, the Combigan Ophthalmic Solution achieved annual sales of approximately $290 million...////...